Evidence map›Paper›PMID 33965374›Full record

ArticleThe Journal of biological chemistry

TBK1 interacts with tau and enhances neurodegeneration in tauopathy.

Measho H Abreha, Shamsideen Ojelade, Eric B Dammer, Zachary T McEachin, Duc M Duong, Marla Gearing, Gary J Bassell, James J Lah, Allan I Levey, Joshua M Shulman and 1 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Multi-omic phenotyping of iPSC-derived neurons harboring thebioRxiv : the preprint server for biology · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Measho H AbrehaDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
Shamsideen OjeladeDepartment of Neurology, Baylor College of Medicine, Houston, Texas, USA; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, USA.
Eric B DammerDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Zachary T McEachinCenter for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia, USA.
Duc M DuongDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Marla GearingCenter for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Gary J BassellCenter for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia, USA.
James J LahCenter for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Allan I LeveyCenter for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Joshua M ShulmanDepartment of Neurology, Baylor College of Medicine, Houston, Texas, USA; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA; Department of Neuroscience, Baylor College of Medicine, Houston, Texas, USA. Electronic address: Joshua.Shulman@bcm.edu.
Nicholas T SeyfriedDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: nseyfri@emory.edu.
Emory University · USBaylor College of Medicine · US

Funding

The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Amy D Rodriguez · 2020 to 2026
$29.0M
The Emory Alzheimer's Disease CenterP50AG025688 · NIA · EMORY UNIVERSITY · PI WALKER, LARY C · 2005 to 2019
$25.7M
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's diseaseR01AG061800 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Christopher A. Gaiteri, Jeremy H. Herskowitz · 2018 to 2026
$6.9M
Functional Dissection of Alzheimer's Disease Networks in Drosophila: from Association to Causal Modulators of Age-Dependent NeurodegerationR01AG057339 · NIA · BAYLOR COLLEGE OF MEDICINE · PI BOTAS, JUAN, LIU, ZHANDONG · 2017 to 2021
$3.8M
Tau-Spliceosome Interactions in Alzheimer's DiseaseR01AG053960 · NIA · BAYLOR COLLEGE OF MEDICINE · PI SEYFRIED, NICHOLAS THOMAS, SHULMAN, JOSHUA M · 2016 to 2020
$3.2M
Brain - Plasma Proteomics Biomarker Discovery and Validation in the US and UKRF1AG057471 · NIA · EMORY UNIVERSITY · PI BENNETT, DAVID ALAN, LEVEY, ALLAN I · 2017 to 2017
$3.2M
Building a high-resolution multi-omic AD interactome with the AMP-AD and M2OVE-AD ProjectsRF1AG057470 · NIA · EMORY UNIVERSITY · PI HAJJAR, IHAB M, SEYFRIED, NICHOLAS THOMAS · 2017 to 2017
$3.1M
Functional Validation of the CD2AP Susceptibility Network in Alzheimer's DiseaseR01AG050631 · NIA · BAYLOR COLLEGE OF MEDICINE · PI SHULMAN, JOSHUA M · 2016 to 2020
$2.5M
NIA NIH HHS P30 AG066511NIA NIH HHS P50 AG025688NIA NIH HHS R01 AG050631NIA NIH HHS R01 AG053960NIA NIH HHS R01 AG057339NIA NIH HHS R01 AG061800NIA NIH HHS RF1 AG057470NIA NIH HHS RF1 AG057471NIA NIH HHS U01 AG061357
6 · The paper itself

Abstract

One of the defining pathological features of Alzheimer's disease (AD) is the deposition of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau in the brain. Aberrant activation of kinases in AD has been suggested to enhance phosphorylation and toxicity of tau, making the responsible tau kinases attractive therapeutic targets. The full complement of tau-interacting kinases in AD brain and their activity in disease remains incompletely defined. Here, immunoaffinity enrichment coupled with mass spectrometry (MS) identified TANK-binding kinase 1 (TBK1) as a tau-interacting partner in human AD cortical brain tissues. We validated this interaction in human AD, familial frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) caused by mutations in MAPT (R406W & P301L) and corticobasal degeneration (CBD) postmortem brain tissues as well as human cell lines. Further, we document increased TBK1 activation in both AD and FTDP-17 and map TBK1 phosphorylation sites on tau based on in vitro kinase assays coupled to MS. Lastly, in a Drosophila tauopathy model, activating expression of a conserved TBK1 ortholog triggers tau hyperphosphorylation and enhanced neurodegeneration, whereas knockdown had the reciprocal effect, suppressing tau toxicity. Collectively, our findings suggest that increased TBK1 activation may promote tau hyperphosphorylation and neuronal loss in AD and related tauopathies.

Indexed as

Protein Interaction MapsAlzheimer DiseaseAnimalsDrosophilaFemaleHEK293 CellsHumansMaleProtein Serine-Threonine KinasesTauopathiestau ProteinsMAPT protein, humanProtein Serine-Threonine Kinasestau ProteinsTBK1 protein, humanAlzheimer’s disease (AD)co-immunoprecipitation (co-IP)Drosophilafamilial frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)IκB kinase (IKK)mass spectrometry (MS)microtubule-associated protein tau (MAPT)neurofibrillary tangles (NFTs)posttranslational modification (PTM)TANK-binding kinase 1 (TBK1)

Identifiers

PMID33965374
PMCPMC8191334
OpenAlexW3162078396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.